12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iluvien fluocinolone acetonide intravitreal implant regulatory update

The U.K.'s NICE issued final guidance recommending the use of Iluvien fluocinolone acetonide intravitreal implant from Alimera for a subset of patients with chronic diabetic macular edema (DME) that is insufficiently responsive to available therapies. The drug is only recommended in pseudophakic patients - those who had already had...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >